Evidence map›Paper›PMID 39830037›Full record

ArticleFrontiers in cellular neuroscience2024

Case report: Atypical young case of MV1 Creutzfeldt-Jakob disease with unusually long survival.

Lucie Yeongran Ahn, Mark L Cohen, Ignazio Cali, Tia Russell, Jessica Ludwig, Xun Jia, Alberto Bizzi, Lawrence B Schonberger, Ryan A Maddox, Rohini Paul and 4 more

Abstract readCase Reports
In one paragraph

Article in Frontiers in cellular neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lucie Yeongran AhnMedical Scientist Training Program, Case Western Reserve University, Cleveland, OH, United States.
Mark L CohenDepartment of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH, United States.
Ignazio CaliDepartment of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH, United States.
Tia RussellNational Prion Disease Pathology Surveillance Center, Case Western Reserve University, School of Medicine, Cleveland, OH, United States.
Jessica LudwigNational Prion Disease Pathology Surveillance Center, Case Western Reserve University, School of Medicine, Cleveland, OH, United States.
Xun JiaNational Prion Disease Pathology Surveillance Center, Case Western Reserve University, School of Medicine, Cleveland, OH, United States.
Alberto BizziNeuroradiology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Neurologico Carlo Besta, Milan, Italy.
Lawrence B SchonbergerCenters for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services (USDHHS), Atlanta, GA, United States.
Ryan A MaddoxCenters for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services (USDHHS), Atlanta, GA, United States.
Rohini PaulDepartment of Psychiatry, Kaiser Permanente San Jose Medical Center, Graduate Medical Education, San Jose, CA, United States.
Tania C GhazarianDepartment of Psychiatry, Loma Linda University School of Medicine, Graduate Medical Education, Loma Linda, CA, United States.
Jaspreet GarchaDepartment of Internal Medicine, Community Memorial Health Systems, Ventura, CA, United States.
Mostafa HammoudiDepartment of Neurology, Community Memorial Health Systems, Ventura, CA, United States.
Brian Stephen ApplebyDepartment of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH, United States.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
NIGMS NIH HHS T32 GM007250
6 · The paper itself

Abstract

Creutzfeldt-Jakob disease (CJD) is a rare, fatal, rapidly progressive neurodegenerative disease resulting from an accumulation of misfolded prion proteins (PrP). CJD affects 1-2 new individuals per million each year, and the sporadic type accounts for 90% of those cases. Though the median age at onset and disease duration vary depending on the subtype of sporadic CJD (sCJD), the disease typically affects middle-aged to elderly individuals with a median survival of 4-6 months. sCJD in younger individuals is extremely rare. Here, we present a 21-year-old female who died with a sporadic prion disease. She presented with psychiatric symptoms followed by a rapidly progressive neurocognitive and motor decline. EEG was negative for periodic sharp wave complexes; however, brain MRI was suggestive of prion disease. The cerebrospinal fluid (CSF) real-time quaking-induced conversion (RT-QuIC) assay was indeterminate. Neuropathologic examination at autopsy revealed severe neuronal loss and gliosis with secondary white matter degeneration but minimal spongiform changes and PrP deposits in the cerebellum and neocortex by immunohistochemistry. Absence of pathogenic mutations and methionine/valine heterozygosity at codon 129 of the prion protein gene (PRNP), atypical type 1 protease-resistant PrP that lacks or shows underrepresentation of the diglycosylated PrP isoform by western blot analysis, and no acquired prion disease risk factors resulted in a final diagnosis of atypical sCJD. Very young onset sCJD often has atypical clinical presentations and disease progression, neuropathological examination results, and/or laboratory test results that may confound diagnosis. It is critical to perform thorough, comprehensive evaluations to make an accurate diagnosis, which includes autopsy confirmation with histology, prion protein typing and prion gene sequencing.

Indexed as

Creutzfeldt-Jakob disease (CJD)prion diseaserapidly progressing dementiasporadic CJD (sCJD)young-onset CJD

Identifiers

PMID39830037
PMCPMC11739107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.